Xtl Biopharmaceuticals (XTLB) Other Accumulated Expenses (2009 - 2012)

Xtl Biopharmaceuticals (XTLB) has reported Other Accumulated Expenses for 4 consecutive years, with $847000.0 the latest figure, recorded in Q3 2012.

• Quarterly Other Accumulated Expenses rose 61.33% year-over-year to $847000.0 in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $847000.0 (up 61.33% YoY) and the FY2011 annual result came in at $541000.0, down 28.82% from the prior year.
• Other Accumulated Expenses advanced to $847000.0 in Q3 2012 per XTLB's latest filing, from $541000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for XTLB reached as high as $847000.0 in Q3 2012 and fell as low as $516000.0 in Q4 2009.
• A 4-year average of $646000.0 and a median of $614000.0 in 2010 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2011 — Other Accumulated Expenses fell 28.82% — and 2012, when it surged 61.33%.
• Year by year, Other Accumulated Expenses stood at $516000.0 in 2009, then jumped by 47.29% to $760000.0 in 2010, then retreated by 28.82% to $541000.0 in 2011, then jumped by 56.56% to $847000.0 in 2012.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $847000.0, $541000.0, and $525000.0 for Q3 2012, Q4 2011, and Q3 2011 respectively.